Search Images Maps Play YouTube News Gmail Drive More »
Settings | Sign in

Botulinum toxin

Botulinum Toxin Market Research Report Now Available at Research Corridor

RD News Mag - ‎May 21, 2016‎
Research Corridor has published a new research study titled “Botulinum Toxin Market - Growth, Share, Opportunities, Competitive Analysis and Forecast, 2015 - 2022”.

Calculating SPC application period based on variation of existing marketing authorisation

Lexology (registration) - ‎16 hours ago‎
The applicant was the owner of European Patent (EP) 0 758 900 for botulinum toxin, which was used to reduce migraine pain. The patent was granted on April 10 2002.

Revance injectable outperforms Botox

ModernMedicine - ‎4 hours ago‎
Separately, independent research conducted in 2001 by Jean Carruthers, M.D., clinical professor of ophthalmology, University of British Columbia, and botulinum toxin pioneer, on Botox had shown that increased dosing does not result in meaningfully ...

Botox For My Birthday: Why I Got Botox At Just 25 Years Old

Hollywood Life - ‎May 25, 2016‎
As you get older, these become damaged and combined with constant muscle movement, the skin is more prone to wrinkling,” said Dr.

Allergan's Botox Vista receives Japanese marketing approval to treat crow's feet lines

pharmabiz.com - ‎May 24, 2016‎
Allergan plc, a leading global pharmaceutical company, announced that the Japanese Ministry of Health, Labour and Welfare has approved an additional use for Botox Vista (Allergan's botulinum toxin type A product) as a treatment for crow's feet lines (CFL).

Dermatologists pioneer top nonsurgical cosmetic procedures

ModernMedicine - ‎15 minutes ago‎
In fact, dermatology ranked higher than plastic surgery, ophthalmology, ENT, nursing, pharmacology and other specialties in botulinum toxin to treat skin aging, laser hair removal, chemical peels, cryolipolysis, calcium hydroxylapatite fillers for ...

EXEL Rises On Trial Data, XNPT Agrees To Be Acquired, NVO Faces FDA Panel Today

Nasdaq - ‎May 23, 2016‎
(RTTNews.com) - Allergan plc's ( AGN ) botulinum toxin type A product, referred to as Botox Vista in Japan, has been approved by the Japanese Ministry of Health, Labour and Welfare for the temporary improvement in the appearance of lateral canthal ...

You're Reading: fastcoexist / Emotional Empathy Gets Harder Once You've Frozen Your Face With Botox

Co.Exist - ‎May 24, 2016‎
In a cruel twist of fate, it turns out that people vain enough to have botulinum toxin injected into their faces to avoid wrinkles may also have their own emotional abilities stunted.

New migraine drugs promise relief — but at a steep price

The Verge - ‎May 24, 2016‎
Botox - the only botulinum toxin that's FDA approved to treat patients that have 15 or more migraines a month - is the most expensive migraine treatment.

7 Conditions That Botox May Help Treat

Live Science - ‎May 23, 2016‎
Botox, a trademark that's short for botulinum toxin, is a neuromuscular blocker, which means it paralyzes the muscle into which it is injected, said Dr.

Revance Therapeutics Inc (RVNC) Jumps 9.84% on May 24

Equities.com - ‎22 hours ago‎
Revance Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in the development, manufacturing and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic applications. Revance Therapeutics ...

BRIEF-Allergan's botox wins Japanese approval to treat crow's feet lines

Reuters - ‎May 23, 2016‎
May 23 Allergan Plc. * Allergan's botox vista (botulinum toxin type a) receives national marketing authorisation in japan for treatment of crow's feet lines in adult patients.

Kinematic Technology Helps Treat Patients with Tremors

HospiMedica (registration) - ‎4 hours ago‎
The data helps alleviate functional disability caused by essential tremor by objectively individualizing and personalizing injection parameters for botulinum toxin type A (BoNT-A). The researchers conducted a 38-week open label study of 24 people ...

Revance Therapeutics Inc (NASDAQ:RVNC)'s Company Shares Decreased 11.85% After Low Volatility

The Post - ‎May 24, 2016‎
According to Zacks Investment Research, “Revance Therapeutics, Inc. is a biopharmaceutical company which focuses on the development, manufacture and commercialization of novel botulinum toxin products for various aesthetic and therapeutic ...
See realtime coverage

20 Things You Never Knew About Botox

Refinery29 - ‎May 21, 2016‎
With the influx of new skin-care procedures, treatments, and products that has hit the market in recent years, one has truly lasted the test of time - 14 years, to be exact - and it seems to be getting even more popular.

Forget Frozen Foreheads: Dr. Kenneth Steinsapir's Microdroplet Lift® is the Secret to Keeping Botox Secret

GlobeNewswire (press release) - ‎May 17, 2016‎
Los Angeles, CA, May 17, 2016 (GLOBE NEWSWIRE) -- Leading oculoplastic surgeon Kenneth Steinsapir, M.D., introduces the new face of cosmetic botulinum toxin (Botox, Xeomin, Dysport) with his patented Microdroplet Lift®. For the first time, individuals ...

Korea sees first biopharma trade surplus in 6 years

The Korea Herald - ‎May 22, 2016‎
The surplus comes on the heels of successful exports of Celltrion's Remsima and the replacement of botulinum toxin imports by their Korean counterparts, the ministry said.
See realtime coverage

Team develops 'life-altering' tremor control

London Free Press - ‎May 19, 2016‎
That new technology, for the first time, enables clinicians to precisely inject a drug called botulinum toxin type A to reduce tremors without causing undesirable side-effects such as weakness.

Ipsen partners with IMCB to advance understanding and research of Botulinum Neurotoxin Biology

News-Medical.net - ‎May 16, 2016‎
By combining Ipsen's leading expertise in BoNT recombinant engineering and biology with IMCB's extensive knowledge and expertise in the fields of membrane and toxin trafficking and RNA interference screening, as well as in RNA interference screening, ...
 -